| Size | Price | Stock | Qty |
|---|---|---|---|
| 2g |
|
||
| 5g |
|
||
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
Purity: ≥98%
Piracetam (BRN-1526393; UCB-6215; Cl-871; Breinox; Ciclofalina; Euvifor; Gabacet; Nootron) is a cyclized derivative of the neurotransmitter gamma-aminobutyric acid (GABA) that has been approved for use in the treatment of a wide range of cognitive disorders. Piracetam is considered to be both a nootropic and a neuroprotective agent. Piracetam is a positive allosteric modulator of the AMPA receptor. It is believed to act on ion channels or ion carriers, thus leading to increased neuron excitability.
| ln Vitro |
In a concentration-dependent manner, piracetam (UCB-6215) can greatly reduce the fusogenic and destabilizing effect of Abeta 29–42. Piracetam preincubation, at a piracetam/peptide ratio of 960, for 20 minutes prior to Abeta 29-42 addition virtually eliminates the mixture of the two fluorescent probes. Piracetam/lipid preincubation virtually eliminates the peptide-induced calcein release in a dose-dependent manner (piracetam/peptide ratios ranging from 9.6 to 960)[1].
|
||
|---|---|---|---|
| ln Vivo |
Age-related changes in membrane fluidity in mice, rats, and humans are demonstrated by decreased anisotropy of the membrane-bound fluorescence probe 1,6-diphenyl-1,3,5-hexatriene (DPH) in the presence of piracetam (UCB-6215) at concentrations less than 1.0 mM prior to preincubation. In some brain regions of both young and old rats, piracetam (UCB-6215) (300 mg/kg once daily) dramatically enhances membrane fluidity; however, in young rats, it has no discernible effect[2]. (UCB-6215) (300 mg/kg daily for 6 weeks) increases membrane fluidity in all brain regions except the cerebellum in old rats and only enhances active avoidance learning in these rats. Additionally, NMDA receptor density in the hippocampus and muscarinic cholinergic receptor densities in the frontal cortex, striatum, and to a lesser extent in the hippocampus of rats are improved by piracetam (UCB-6215) (300 mg/kg daily for 6 weeks)[3].
|
||
| Animal Protocol |
|
||
| References |
[1]. Mingeot-Leclercq, M.P., et al., Piracetam inhibits the lipid-destabilising effect of the amyloid peptide Abeta C-terminal fragment. Biochim Biophys Acta, 2003. 1609(1): p. 28-38.
[2]. Muller, W.E., et al., Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol, 1997. 53(2): p. 135-40. [3]. Scheuer, K., et al., Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry, 1999. 32 Suppl 1: p. 10-6. |
| Molecular Formula |
C6H10N2O2
|
|
|---|---|---|
| Molecular Weight |
142.16
|
|
| CAS # |
7491-74-9
|
|
| Related CAS # |
Piracetam-d8;1329799-64-5;Piracetam-d6
|
|
| SMILES |
O=C(N)CN1C(CCC1)=O
|
|
| InChi Key |
SIXPSGNZQPKXTG-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C6H10N2O2/c1-5(9)7-8-4-2-3-6(8)10/h2-4H2,1H3,(H,7,9)
|
|
| Chemical Name |
1-Acetamido-2-pyrrolidinone
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.0343 mL | 35.1716 mL | 70.3433 mL | |
| 5 mM | 1.4069 mL | 7.0343 mL | 14.0687 mL | |
| 10 mM | 0.7034 mL | 3.5172 mL | 7.0343 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA